 Julie Harral
Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 16 | 2023 | 1736 | 0.800 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 6 | 2011 | 48 | 0.410 |
Why?
| | Anemia, Sickle Cell | 3 | 2020 | 215 | 0.400 |
Why?
| | Lung | 13 | 2023 | 3521 | 0.380 |
Why?
| | Pulmonary Artery | 10 | 2022 | 1024 | 0.340 |
Why?
| | Heart Ventricles | 7 | 2023 | 723 | 0.340 |
Why?
| | Hypoxia | 7 | 2023 | 956 | 0.310 |
Why?
| | Hemoglobins | 2 | 2019 | 308 | 0.270 |
Why?
| | Microvessels | 3 | 2018 | 66 | 0.260 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2012 | 409 | 0.240 |
Why?
| | Endothelial Cells | 5 | 2023 | 677 | 0.200 |
Why?
| | Vascular Remodeling | 2 | 2022 | 153 | 0.190 |
Why?
| | Animals | 27 | 2023 | 31565 | 0.190 |
Why?
| | Scleroderma, Systemic | 1 | 2022 | 90 | 0.190 |
Why?
| | Cigarette Smoking | 1 | 2022 | 74 | 0.180 |
Why?
| | Mice | 19 | 2023 | 14841 | 0.180 |
Why?
| | Beta vulgaris | 1 | 2020 | 4 | 0.180 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 221 | 0.170 |
Why?
| | Emulsions | 1 | 2019 | 42 | 0.170 |
Why?
| | Respiratory Tract Infections | 1 | 2023 | 319 | 0.170 |
Why?
| | Pulmonary Emphysema | 1 | 2022 | 267 | 0.160 |
Why?
| | Pulmonary Edema | 1 | 2019 | 109 | 0.160 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 55 | 0.160 |
Why?
| | Evans Blue | 1 | 2018 | 6 | 0.160 |
Why?
| | Down Syndrome | 1 | 2023 | 335 | 0.160 |
Why?
| | Disease Models, Animal | 7 | 2023 | 3498 | 0.150 |
Why?
| | Blood Vessels | 3 | 2016 | 179 | 0.150 |
Why?
| | Fluorocarbons | 1 | 2019 | 94 | 0.150 |
Why?
| | Capillary Permeability | 1 | 2018 | 137 | 0.150 |
Why?
| | Rats | 8 | 2022 | 4913 | 0.140 |
Why?
| | Physical Exertion | 1 | 2018 | 209 | 0.140 |
Why?
| | Fibrosis | 1 | 2019 | 452 | 0.140 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 295 | 0.140 |
Why?
| | Water | 1 | 2019 | 394 | 0.130 |
Why?
| | Rats, Sprague-Dawley | 6 | 2019 | 2182 | 0.130 |
Why?
| | Ventricular Remodeling | 2 | 2023 | 224 | 0.130 |
Why?
| | Neprilysin | 1 | 2016 | 47 | 0.130 |
Why?
| | Calcium Channels, T-Type | 2 | 2005 | 16 | 0.130 |
Why?
| | Mice, Transgenic | 7 | 2022 | 1947 | 0.130 |
Why?
| | Myocytes, Smooth Muscle | 3 | 2007 | 236 | 0.120 |
Why?
| | Muscle Contraction | 1 | 2018 | 388 | 0.120 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 907 | 0.120 |
Why?
| | Adaptation, Physiological | 1 | 2018 | 484 | 0.120 |
Why?
| | Cell Proliferation | 5 | 2018 | 2173 | 0.120 |
Why?
| | Endotoxins | 1 | 2015 | 211 | 0.120 |
Why?
| | Altitude | 1 | 2018 | 435 | 0.120 |
Why?
| | Macrophages | 2 | 2019 | 1259 | 0.110 |
Why?
| | Oxygen | 1 | 2018 | 851 | 0.110 |
Why?
| | Apoptosis | 4 | 2018 | 2349 | 0.110 |
Why?
| | Vitamin D | 1 | 2015 | 340 | 0.100 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 830 | 0.100 |
Why?
| | Cytoskeleton | 1 | 2011 | 176 | 0.090 |
Why?
| | Heart Failure | 1 | 2023 | 1958 | 0.090 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2012 | 197 | 0.090 |
Why?
| | Histone Deacetylases | 1 | 2012 | 194 | 0.090 |
Why?
| | Transgenes | 2 | 2008 | 170 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2022 | 4680 | 0.080 |
Why?
| | Ventricular Function, Right | 3 | 2023 | 256 | 0.080 |
Why?
| | Gene Expression Regulation | 4 | 2016 | 2321 | 0.080 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2023 | 141 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2018 | 1468 | 0.080 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 72 | 0.080 |
Why?
| | Blood Pressure | 5 | 2018 | 1531 | 0.080 |
Why?
| | Mutant Proteins | 1 | 2008 | 95 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2008 | 398 | 0.070 |
Why?
| | Muscle, Smooth | 1 | 2008 | 142 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 126 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2011 | 742 | 0.070 |
Why?
| | Pulmonary Circulation | 3 | 2019 | 407 | 0.070 |
Why?
| | Galectin 1 | 1 | 2006 | 2 | 0.070 |
Why?
| | Cells, Cultured | 6 | 2012 | 3861 | 0.070 |
Why?
| | Hyperoxia | 1 | 2007 | 99 | 0.070 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2006 | 31 | 0.060 |
Why?
| | Male | 11 | 2023 | 55396 | 0.060 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2006 | 82 | 0.060 |
Why?
| | Multigene Family | 1 | 2006 | 190 | 0.060 |
Why?
| | Femur | 1 | 2006 | 191 | 0.060 |
Why?
| | Neovascularization, Physiologic | 1 | 2006 | 174 | 0.060 |
Why?
| | Leukocyte Common Antigens | 3 | 2008 | 75 | 0.060 |
Why?
| | Pneumonia | 1 | 2009 | 563 | 0.060 |
Why?
| | Female | 10 | 2023 | 59325 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2006 | 445 | 0.050 |
Why?
| | Stem Cells | 1 | 2007 | 541 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2008 | 2090 | 0.050 |
Why?
| | Biology | 1 | 2023 | 79 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 429 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2022 | 73 | 0.050 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 97 | 0.050 |
Why?
| | CDC2-CDC28 Kinases | 1 | 2001 | 18 | 0.050 |
Why?
| | Doxycycline | 2 | 2016 | 54 | 0.050 |
Why?
| | Leukocytes | 1 | 2022 | 272 | 0.050 |
Why?
| | Mutation | 1 | 2011 | 3338 | 0.050 |
Why?
| | Familial Primary Pulmonary Hypertension | 2 | 2011 | 191 | 0.050 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2022 | 250 | 0.040 |
Why?
| | Vascular Resistance | 2 | 2015 | 340 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 918 | 0.040 |
Why?
| | Cell Division | 3 | 2009 | 754 | 0.040 |
Why?
| | Nitrates | 1 | 2020 | 71 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 924 | 0.040 |
Why?
| | Phenylpropionates | 1 | 2019 | 16 | 0.040 |
Why?
| | Humans | 13 | 2023 | 114043 | 0.040 |
Why?
| | Animals, Newborn | 2 | 2015 | 777 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1128 | 0.040 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2019 | 26 | 0.040 |
Why?
| | Pyridazines | 1 | 2019 | 46 | 0.040 |
Why?
| | Fatty Acids | 1 | 2022 | 380 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 1 | 2001 | 283 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 159 | 0.040 |
Why?
| | Gadolinium | 1 | 2019 | 73 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2020 | 212 | 0.040 |
Why?
| | AC133 Antigen | 2 | 2008 | 19 | 0.040 |
Why?
| | Kidney Tubules, Proximal | 1 | 2019 | 113 | 0.040 |
Why?
| | Tamoxifen | 1 | 2019 | 190 | 0.040 |
Why?
| | Signal Transduction | 2 | 2011 | 4501 | 0.040 |
Why?
| | Endothelins | 1 | 2018 | 61 | 0.040 |
Why?
| | Myofibroblasts | 1 | 2019 | 115 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2001 | 549 | 0.040 |
Why?
| | Cell Lineage | 1 | 2019 | 308 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2020 | 587 | 0.040 |
Why?
| | Hemolysis | 1 | 2018 | 143 | 0.040 |
Why?
| | Pyrroles | 1 | 2018 | 181 | 0.040 |
Why?
| | Proteomics | 1 | 2023 | 815 | 0.040 |
Why?
| | Acclimatization | 1 | 2018 | 147 | 0.030 |
Why?
| | Enzyme Activation | 2 | 2011 | 771 | 0.030 |
Why?
| | Glycoproteins | 2 | 2008 | 304 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2020 | 459 | 0.030 |
Why?
| | Microcirculation | 2 | 2007 | 133 | 0.030 |
Why?
| | Indoles | 1 | 2018 | 300 | 0.030 |
Why?
| | Substance P | 1 | 2016 | 44 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 428 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2020 | 1656 | 0.030 |
Why?
| | Duodenum | 1 | 2016 | 62 | 0.030 |
Why?
| | Antigens, CD | 2 | 2008 | 440 | 0.030 |
Why?
| | Phosphorylation | 2 | 2011 | 1558 | 0.030 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2015 | 29 | 0.030 |
Why?
| | Elastin | 1 | 2015 | 78 | 0.030 |
Why?
| | Phenotype | 3 | 2011 | 2784 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 2007 | 1003 | 0.030 |
Why?
| | Blotting, Western | 2 | 2009 | 1143 | 0.030 |
Why?
| | RNA, Small Interfering | 2 | 2007 | 534 | 0.030 |
Why?
| | Gene Expression Profiling | 2 | 2011 | 1519 | 0.030 |
Why?
| | Promoter Regions, Genetic | 2 | 2011 | 1131 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2018 | 817 | 0.030 |
Why?
| | Transfection | 2 | 2007 | 863 | 0.030 |
Why?
| | Peptides | 2 | 2008 | 848 | 0.030 |
Why?
| | Genotype | 2 | 2011 | 1757 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2371 | 0.030 |
Why?
| | rac GTP-Binding Proteins | 1 | 2011 | 33 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2011 | 51 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2009 | 2562 | 0.020 |
Why?
| | Chronic Disease | 2 | 2008 | 1577 | 0.020 |
Why?
| | Receptor, TIE-2 | 1 | 2011 | 12 | 0.020 |
Why?
| | Neuropeptides | 1 | 2011 | 63 | 0.020 |
Why?
| | rac1 GTP-Binding Protein | 1 | 2011 | 55 | 0.020 |
Why?
| | Ventricular Pressure | 1 | 2011 | 39 | 0.020 |
Why?
| | Benzamides | 1 | 2012 | 168 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2011 | 261 | 0.020 |
Why?
| | Gene Expression | 2 | 2009 | 1417 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2011 | 132 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2012 | 421 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2004 | 1075 | 0.020 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2009 | 48 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 374 | 0.020 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2009 | 61 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 50 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 21 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2006 | 2698 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2011 | 1228 | 0.020 |
Why?
| | Smad Proteins | 1 | 2008 | 39 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 419 | 0.020 |
Why?
| | Hematocrit | 1 | 2008 | 86 | 0.020 |
Why?
| | Thrombosis | 1 | 2011 | 295 | 0.020 |
Why?
| | Systole | 1 | 2008 | 176 | 0.020 |
Why?
| | Endothelium | 1 | 2008 | 109 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2009 | 177 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 164 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 249 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 86 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 541 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 280 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2007 | 125 | 0.020 |
Why?
| | Rats, Nude | 1 | 2006 | 26 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 9049 | 0.020 |
Why?
| | Time Factors | 2 | 2007 | 6077 | 0.020 |
Why?
| | Cell Cycle | 1 | 2008 | 541 | 0.020 |
Why?
| | Capillaries | 1 | 2006 | 90 | 0.020 |
Why?
| | Mibefradil | 1 | 2005 | 5 | 0.020 |
Why?
| | Electrocardiography | 1 | 2008 | 561 | 0.020 |
Why?
| | DNA Primers | 1 | 2006 | 508 | 0.020 |
Why?
| | Muscle Proteins | 1 | 2007 | 210 | 0.020 |
Why?
| | Diltiazem | 1 | 2005 | 23 | 0.020 |
Why?
| | Edema | 1 | 2006 | 119 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2005 | 239 | 0.020 |
Why?
| | Antigens, Polyomavirus Transforming | 1 | 2004 | 14 | 0.020 |
Why?
| | Cycloheximide | 1 | 2004 | 53 | 0.010 |
Why?
| | Caspase 8 | 1 | 2004 | 43 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2004 | 47 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2004 | 40 | 0.010 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2004 | 42 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2004 | 93 | 0.010 |
Why?
| | Sheep | 1 | 2006 | 761 | 0.010 |
Why?
| | Pregnancy | 1 | 2015 | 5499 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2004 | 170 | 0.010 |
Why?
| | Genomics | 1 | 2008 | 633 | 0.010 |
Why?
| | Actins | 1 | 2006 | 376 | 0.010 |
Why?
| | Caspases | 1 | 2004 | 243 | 0.010 |
Why?
| | Organ Specificity | 1 | 2004 | 266 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 2006 | 436 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2007 | 333 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2114 | 0.010 |
Why?
| | Telomerase | 1 | 2004 | 205 | 0.010 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2004 | 307 | 0.010 |
Why?
| | Tritium | 1 | 2001 | 66 | 0.010 |
Why?
| | Cyclin E | 1 | 2001 | 21 | 0.010 |
Why?
| | Thymidine | 1 | 2001 | 58 | 0.010 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2001 | 32 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2001 | 69 | 0.010 |
Why?
| | Erythrocytes | 1 | 2006 | 568 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2008 | 2550 | 0.010 |
Why?
| | Mutagenesis | 1 | 2001 | 168 | 0.010 |
Why?
| | Inflammation | 1 | 2011 | 2464 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2008 | 1735 | 0.010 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2001 | 111 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 1836 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2007 | 1695 | 0.010 |
Why?
| | Blood Proteins | 1 | 2001 | 222 | 0.010 |
Why?
| | Mitochondria | 1 | 2004 | 744 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1311 | 0.010 |
Why?
| | Biomarkers | 1 | 2007 | 3397 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2007 | 5038 | 0.010 |
Why?
| | DNA | 1 | 2001 | 1350 | 0.010 |
Why?
| | Hypertension | 1 | 2001 | 1052 | 0.010 |
Why?
| | Child | 1 | 2008 | 18400 | 0.010 |
Why?
| | Middle Aged | 1 | 2008 | 26605 | 0.000 |
Why?
| | Adult | 1 | 2008 | 30375 | 0.000 |
Why?
|
|
Harral's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|